Urispas (Flavoxate HCl) Drug Information: Overdosage and Contraindications

May 27, 2012

*Urinary incontinence (UI) in men facts Medically Edited by: Melissa Conrad Stöppler, MD

The definition of urinary incontinence in men is the unintentional loss of urine. Weak bladder muscles, overactive bladder muscles, certain prostate conditions, and nerve damage are just some of the possible underlying causes of urinary incontinence in men.
There are different types of urinary incontinence in men, including stress incontinence, urge incontinence, and overflow incontinence.
Diagnosis of urinary incontinence in men may involve a physical exam, an ultrasound, urodynamic testing, and tests including an electroencephalogram (EEG) and an electromyogram (EMG). The doctor will also take a medical history and may recommend keeping a bladder diary.
Treatment of urinary incontinence in men may include behavioral treatments, like bladder training and Kegel exercises, medication, surgery, or...

Urispas

font size

The oral LD₅₀ for flavoxate HCl in rats is 4273 mg/kg. The oral LD₅₀ for flavoxate HCl in mice is 1837 mg/kg.

It is not known whether flavoxate HCI is dialyzable.

Urispas (flavoxate HCl) is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.